Innova Captab

Innova Captab R&D Expenses

The Research & Development Expenses of Innova Captab (INNOVACAP.NS) as of Oct 24, 2026 is 69.95 M INR. In the previous year, Research & Development Expenses was 65.50 M INR — a change of 6.79% (higher).

R&D Expenses

69.95 MINR

YoY

6.79%

Last updated:

Research & Development Expenses of Innova Captab is 2026 69.95 M INR. Research & Development Expenses of Innova Captab was 2025 65.50 M INR. It decreases by 6.79% higher compared to the previous year.

The Innova Captab R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2024
57.00 M INR
Jan 1, 2025
65.50 M INR
Jan 1, 2026
69.95 M INR
The Innova Captab R&D Expenses history
YEARR&D ExpensesYoY
69.95 MINR+6.79%
65.50 MINR+14.91%
57.00 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innova Captab Stock analysis

What does Innova Captab do? Innova Captab Ltd generates revenue through its CDMO business, which offers research, product development, and manufacturing services to clients in the pharmaceutical sector. The company also earns from its domestic branded generics business, developing, manufacturing, and distributing generic formulation products under its own brand names across India via online and offline channels. Additionally, Innova Captab sells its generic drug products through various e-commerce pharmacy sites. The company's diversified portfolio includes tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. Its international branded generic product business focuses on exporting branded generic products globally. Innova Captab's primary customers are pharmaceutical companies seeking CDMO services, Indian consumers purchasing generic medicines through retail and online pharmacies, and international buyers of branded generic products. The domestic market segment is served through branded generics sold under the company's own brand names, while the international segment targets global markets for branded generic drug exports. The company's value chain spans research and development, manufacturing, drug distribution, marketing, and exports, ensuring comprehensive coverage across the pharmaceutical industry. The company's product segments include CDMO services, domestic branded generics, and international branded generics. CDMO services are provided to pharmaceutical firms requiring outsourced research and manufacturing. Domestic branded generics are marketed in India under the company's brand names through both online and offline channels. International branded generics are exported to global markets, leveraging the company's manufacturing capabilities and product portfolio. Innova Captab's business model integrates all stages of the pharmaceutical value chain, from R&D to exports, to deliver a full-service solution for its clients and customers. Innova Captab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innova Captab stock

Research & Development Expenses of Innova Captab is 69.95 M INR in 2026.

Research & Development Expenses of Innova Captab changed from 65.50 M INR to 69.95 M INR, representing a 6.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Innova Captab since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Innova Captab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Innova Captab

All Key Metrics — Innova Captab